In a recent development, a scientific advisory panel rejected the use of MDMA for treating PTSD, casting doubt on its approval by the FDA. The panel voted against the effectiveness of MDMA in treating PTSD after critiquing the methodology of clinical trials. Gilead Sciences also agreed to pay $40 million to AIDS patients for allegedly marketing an HIV drug without disclosing harmful side effects. The company denied any wrongdoing but settled the dispute with patients. These events shed light on the complexities of drug approval and marketing practices in the healthcare industry.
Source link
We’re reading about MDMA ‘no’ votes, a Gilead settlement
